Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Change in Cash: 2012-2024

Historic Change in Cash for Neurogene (NGNE) over the last 13 years, with Dec 2024 value amounting to -$11.8 million.

  • Neurogene's Change in Cash rose 127.46% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year decrease of 79.58%. This contributed to the annual value of -$11.8 million for FY2024, which is 117.68% down from last year.
  • Per Neurogene's latest filing, its Change in Cash stood at -$11.8 million for FY2024, which was down 117.68% from $66.7 million recorded in FY2023.
  • Neurogene's 5-year Change in Cash high stood at $66.7 million for FY2023, and its period low was -$50.1 million during FY2021.
  • For the 3-year period, Neurogene's Change in Cash averaged around $22.1 million, with its median value being $11.5 million (2022).
  • As far as peak fluctuations go, Neurogene's Change in Cash slumped by 199.50% in 2021, and later spiked by 481.14% in 2023.
  • Over the past 5 years, Neurogene's Change in Cash (Yearly) stood at $50.3 million in 2020, then slumped by 199.50% to -$50.1 million in 2021, then soared by 122.91% to $11.5 million in 2022, then spiked by 481.14% to $66.7 million in 2023, then crashed by 117.68% to -$11.8 million in 2024.